Full Description
Endocrine mechanisms and breast cancer continue to be important subjects for research in cancer medicine. This fifth volume of the ESO Task Force on the endocrine therapy of breast cancer provides the reader with an update of recent developments in the field. The spectrum of the items is remarkably broad and includes the normal breast cell, the cancer cell, mechanisms of resistance to therapeutic agents, new endocrine treatments, the patient with breast cancer, her quality of life, and some public health issues related to the population of women with the disease.
Contents
Normal cell lineages and the phenotype of the breast cancer cell; the oestrogen-related pS2-BCEI protein in breast cancer; do all roads lead to the oestrogen receptor?; Tamoxifen for the treatment of breast cancer in the premenopausal patient; the multi-drug resistance phenotype and its reversal by drugs (with special emphasis on anti-oestrogens); new endocrine agents for breast cancer; prognostic factors in primary breast cancer - second thoughts; the contribution of perturbed epithelial-mesenchymal interactions to cancer pathogenesis; reporting results from adjuvant therapy trials with special emphasis on quality-of-life findings; adjuvant chemoendocrine therapies in pre-and post-menopausal breast cancer.
